We are a Ukrainian company. We stand with our colleagues, friends, family, and with all people of Ukraine. Learn more

Alnylam Pharmaceuticals

Email address and contacts

Alnylam Pharmaceuticals company description

To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. We now have four additional medicines on the market. Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of 1,900+ people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer 3 years in a row ('19-'21), a Boston Globe Top Place to Work 8x in a row ('15-'21) and Fast Company's #1 Best Workplace for Innovators ('22 We are based in Cambridge, U.S., with offices throughout Europe, Asia, and South America. We invite you to connect with us by following us on LinkedIn, Facebook (@AlnylamPharma) Twitter (@Alnylam), Instagram (@AlnylamPharma) and YouTube. See our community guidelines: https://bit.ly/2FcRhJy.

Key Employees

Senior Manager Facilities Operation Japan Asia
Find Email
Daniel Crouch
Head, Ethics and Compliance - U.S. Region
Frank Gaul
Business Development Intern
Manuel Muro
Marketing Director TTR, International Markets
Harry Dmc
Operations Director
Rie Tanaka
Finance Director, Asia
Lovely Thinis
Rare Disease Case Manager
Sign up to open these and 5 more emails in Alnylam Pharmaceuticals
Message error line

Alnylam Pharmaceuticals competitors and alternatives

Myriad Genetics
2423 employees
AGC Biologics
2361 employees
2334 employees
Emergent BioSolutions
2155 employees
2154 employees
Tempus Labs, Inc.
2153 employees
View all competitors

Recently updated team members of Alnylam Pharmaceuticals

Kelley Boucher
Chief Human Resources Officer
Pj Arnold
Medical Science Liaison
Akanksha Mittal
Senior Director, Rare Disease Lead, US Medical Affairs
Paul Medeiros
Associate Director, Manufacturing
Gilles Bertrand
Vice President, Head of Regional Commercial, International
Dalia Cahana-Amitay
Senior Manager, Medical Communications & Publications, Medical Affairs
View all employees

GetProspect Email Finder

Retrieve thousands of email addresses in single click without leaving your current tab. Download for free now!

50 Free emails every month

Add to Chrome

800+ reviews 90,000+ users

Try email finder for Free and reach your ideal customer